Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019

Source: https://www.researchbymarkets.com/report/integrin-beta-3-platelet-membrane-glycoprotein-iiia-or-cd61-or-itgb3-pipeline-review-h1-2019-268239.html

For queries regarding this report: https://www.researchbymarkets.com/sample-request/268239

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutic Products under Development, Key Players in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutics, Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Pipeline Overview, Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Pipeline, Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Pipeline Assessment

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019

Summary

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Integrin beta-3 (?3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease and Immunology which include indications Breast Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Macular Edema, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Rheumatoid Arthritis, Sepsis and Staphylococcus Aureus Septicaemia.

The latest report Integrin Beta 3 – Pipeline Review, H1 2019, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
– The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
BrightGene Bio-Medical Technology Co Ltd
Celltrion Inc
Factor Therapeutics Ltd
Merck & Co Inc
Pliant Therapeutics Inc
SciFluor Life Sciences LLC
Tasly Pharmaceutical Group Co Ltd
Vascular Pharmaceuticals Inc
Virtual Drug Development Inc

Contact Us:

ResearchByMarkets.com

Ritesh Tiwari, Director

enquiry@researchbymarkets.com

USA: +1-800-416-3124

https://www.researchbymarkets.com/aboutus

Follow us on Social Media:

Facebook: https://www.facebook.com/researchbymarkets/

LinkedIn: https://www.linkedin.com/company/researchbymarkets/

Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.